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Abstract NogoA, myelin-associated glycoprotein (MAG)
and oligodendrocyte myelin glycoprotein are CNS myelin
molecules that bind to the neuronal Nogo-66 receptor
(NgR) and inhibit axon growth. The NgR antagonist, sol-
uble NgR1-Fc protein (sNgR-Fc), facilitates axon regen-
eration by neutralizing the inhibitory effects of myelin
proteins in experimental models of CNS injury. Here we
aim to investigate the effect of sNgR-Fc on the
proliferation of neural progenitor cells (NPCs). The hip-
pocampus cells of embryonic rats were isolated and cul-
tured in vitro. The expression of nestin, bIII-Tubulin,
GFAP and Nogo-A on these cells was observed using
immunocytochemistry. In order to investigate the effect on
proliferation of NPCs, sNgR-Fc, MAG-Fc chimera and
Notch1 blocker were added respectively. The total cell
number for the proliferated NPCs was counted. BrdU was
applied and the rate of proliferating cells was examined.
The level of Notch1 was analyzed using Western blotting.
We identified that NogoA is expressed in NPCs. sNgR-Fc
significantly enhanced the proliferation of NPCs in vitro as
indicated by BrdU labeling and total cell count. This pro-
liferation effect was abolished by the administration of
MAG suggesting specificity. In addition, we demonstrate
that sNgR-Fc is a potent activator for Notch1 and Notch1
antagonist reversed the effect of sNgR-Fc on NPC prolif-
eration. Our results suggest that sNgR-Fc may modulate
Nogo activity to induce NPC proliferation via the Notch
pathway.
Keywords Nogo-66 receptor  Rat neural progenitor
cells  Notch1  NogoA  Myelin-associated glycoprotein
Introduction
Neural progenitor cells (NPCs) are capable of self-prolif-
erating and differentiating into the three major cell lineages
of central nervous system (CNS), and has the potential for
replacement of lost or dysfunctional neurons or glial cells.
Stem cell replacement therapy may 1 day become a
promising strategy for CNS injuries and neurodegenerative
disorders. However, the limited regenerative capacity of
both endogenous and grafted NPCs is attributed to the
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inhibition of NPC proliferation and differentiation in situ
by local environmental factors. The proliferation and dif-
ferentiation of NPCs are determined by the effects of
extrinsic and intrinsic signals coming from substrates,
medium components and several complex interactions
among cells. Therefore, a better understanding of the role
of the molecular environment to NPC neurogenesis may be
crucial for developing stem cell therapy.
Several proteins associated with CNS myelin possess
axon growth inhibiting properties. These include NogoA
[1], myelin-associated glycoprotein (MAG) [2], and oli-
godendrocyte myelin glycoprotein (OMgp) [3]. All three
bind the Nogo66 receptor (NgR1) [4] and the paired
immunoglobulin-kuje receptor B (PirB) [5] to mediate their
inhibitory influence. Multiple lines of evidence suggest that
the myelin proteins and NgR1 may affect NPC activities in
addition to the effects on axon regeneration. Besides being
expressed in the adult neurons and weakly in adult non-
neuronal cells, NgR1 is also expressed in the spinal
cord, the brain of chicken and human embryo [6] and in
the NPCs derived from rat spinal cords [7]. NogoA is
expressed in neurons in a variety of areas of both fetal and
adult human and rat brains [8]. It is also expressed in oli-
godendrocyte progenitor cells [9]. NogoA promoted NPCs
to differentiate to the glial lineage while inhibiting their
differentiation into neurons [10]. Nogo-P4 (the active
segment of Nogo-66) inhibited the differentiation of NPCs
derived from rat spinal cords [7]. Since the expression
levels of NogoA, MAG and OMgp are upregulated after
CNS injury, they may be important factors for NPC
neurogenesis.
The NgR1 antagonist, recombinant rat soluble NgR-Fc
fusion protein [11], effectively blocked the interaction of
myelin proteins with NgR1 and has been shown to promote
recovery in rodent models of CNS injuries [12–16].
Notch1 is an important signaling pathway in the embryo-
genesis, hematogenesis and the differentiation of NPCs
during development [17, 18]. Upon activation by Notch
ligands, Notch intracellular domain (NICD) is cleave,
released from the whole receptor, and activated transcrip-
tion of its downstream target genes [19]. So far, Hairy/
Enhancer of Split (Hes) genes appears to be the primary
downstream mediators of Notch signaling. Among them,
Hes5 is considered to be an essential effector of Notch-
mediated activity [20]. In the developing brain, activated
Notch signaling maintains NPCs and promotes prolifera-
tion of neural progenitors [21, 22]. We hypothesize that
NogoA and NgR1 are involved in the proliferation of
NPCs and the NgR antagonist, sNgR-Fc, may affect NPC
proliferation. In this study, we examined the expression of
NogoA in NPCs and investigated whether sNgR-Fc pro-
motes the proliferation of NPCs via Notch signaling
pathway in vitro.
Methods
Preparation of NgR1-Fc Protein
The form of sNgR-Fc used for this study, AA-rNgR(310)-
rFc [12], is an improved variant form of the NgR-ecto-Fc
fusion protein reported previously [15]. This protein com-
prises a 310 amino acid fragment of rat NgR1 fused to a rat
IgG1 Fc fragment, in which Cys266 and Cys309 were
replaced with alanine residues in order to eliminate heter-
ogenous disulfide bonds [23]. The construct was expressed
in Chinese hamster ovary cells, protein was purified, and
binding to Nogo66, OMgp, and MAG was verified using
previously established methods [15]. This modified protein
inhibits the Nogo66-NgR interaction and promotes neurite
growth of rat dorsal root ganglia and cerebellar granule
neurons in vitro with similar potency as the unmodified
sNgR-Fc [12].
Primary Neurosphere Culture, Differentiation
and Immunocytochemistry
The procedures for isolation of embryonic NPCs have been
described previously [24]. The hippocampus of embryonic
day (E) 16 embryo of Sprague–Dawley (SD) rats from
Laboratory Animal Unit, The University of Hong Kong
was dissected, rinsed in cold CMF-HBSS and dissociated
mechanically. The cells were collected by centrifugation
and resuspended in Dulbecco’s modified Eagle’s Medium/
HamF12 (DMEM/F12) supplemented with epidermal
growth factor (EGF; 20 ng/ml, Gibco, CA, USA), basic
fibroblast growth factor (bFGF, 20 ng/ml, Sigma, MO,
USA), B27 supplement (2%, Gibco, CA, USA), N2 sup-
plement (1%, Gibco, CA, USA), penicillin (50 U/ml), and
streptomycin (50 lg/ml). The cells were adjusted to
1 9 105 cells/ml for cell culture. Half of the culture
medium was replaced every 3 days. To identify the cul-
tured cells, some of neurospheres after cultured for 7 days
were plated on poly-L-lysine-coated coverslips and grown
in culture medium. After neurospheres were attached on
the coverslips (2 h), they were fixed with 4% paraformal-
dehyde (PFA) for 20 min, washed, permeated in 0.25%
Triton-X100/phosphate buffered saline (PBS) and blocked
with 10% goat serum. Cells were then incubated with
mouse anti-Nestin (1:100, Santa Cruz Biotechnology, CA,
USA) at 4C for 16 h. After washing, the cells were
incubated with a fluorescent Alexa 568-conjugated sec-
ondary antibody (1:400, Molecular Probes, CA, US) for 2 h
at room temperature. Cell nuclei were counterstained with
40,6-diamidino-2-phenylindole (DAPI, Sigma, MO, USA).
The above neurospheres were harvested, dissociated and
plated as described above, but in culture medium without
EGF and bFGF for initiating and promoting differentiation.
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After 3 days of differentiation, the cells were immuno-
stained using mouse anti-bIII-tubulin antibody (Sigma,
MO, USA) for undifferentiated neural progenitor cells,
rabbit anti-glial fibrillary acidic protein (GFAP) (1:1,000;
Chemicon, Temecula, California, USA) for astrocytes or
mouse anti-Rip (1:50, Abcame, CB, UK) for oligoden-
drocyte, mouse anti-bIII-tubulin antibody (1:1,000, Sigma,
MO, USA) for neurons. The cells were incubated with a
fluorescent Alexa 488 or 568-conjugated secondary anti-
body (1:400, Molecular Probes, CA, US) and Cell nuclei
were counterstained with DAPI (Sigma, MO, USA).
In order to examine the expression of NogoA and
Notch1 in NPCs, the above neurospheres were dissociated
and seeded onto poly-L-lysine-coated coverslips in
1 9 104 cells/well with the above medium. The cells were
then double-immunostained using rabbit anti-NogoA
(1:100, Santa Cruz, Biotechnology, CA, USA) and mouse
anti-Nestin (1:100, Santa Cruz Biotechnology, CA, USA)
or rabbit anti-Notch1 (1:100, Upstate, Temecula, CA,
USA) and mouse anti-Nestin antibodies as described
above.
Proliferation Assay for Neurospheres and NPCs
in Vitro
After 7 days in culture, the neurospheres were treated with
0.25% trypsin for 10 min and then mechanically dissoci-
ated. The dissociated NPCs were seeded onto poly-L-
lysine-coated coverslips in 1 9 104 cells/well with the
500 ll medium. sNgR-Fc of 50, 500, or 1,000 ng/ml was
added to the cultures, respectively. Untreated cultures were
used as control. In order to examine whether the sNgR-Fc
promotes the proliferation of NPCs by inhibiting the effects
of CNS myelin proteins, recombinant rat MAG-Fc chimera
(200 ng/ml, R & D Systems, Inc, MN, USA) was added to
the medium to neutralize sNgR-Fc (500 ng/ml). To confirm
the role of Notch signaling pathway in the proliferation
activity of sNgR-Fc on the NPCs, we used a Notch1
antagonist, MW167 (c-Secretase Inhibitor II, 10 lmol/l,
Calbiochem, CA, USA), to block Notch activity.
Counting the Total Cell Number for the Proliferation
Assay
To analyze neurosphere growth, the volume of living
neurospheres was measured using an inverted microscope
(Axiovert 100, Carl Zeiss, Jena, Germany) and ImageJ
software (National Institute of Health, USA). In order to
determine the cell number, the treated spheres were col-
lected at 24, 48 and 72 h after plating and the cells were
counted as described [25]. The neurospheres in one well
were trypsinized with 2 ml of 19 typsin-EDTA (ethylene-
diaminetetraacetic acid) (0.05% trypsin, 0.02% EDTA-4Na)
(GIBCO, Invitrogen corporation, CA, USA) for 2 min.
Trypsin–EDTA was then removed and cells were incu-
bated at 37C for another 2 min. After incubation, cells
were suspended in 1 ml medium and single-cell suspen-
sions at 2–5 9 105 cells/ml were obtained. Ten ll cell
suspension was loaded to the chamber of hemocytometer
by capillary action and number of cells were counted using
microscope. A total 72 cultures (6 cultures in each con-
centration of sNgR-Fc and control group every day) was
used for the total cell number counting. The volume of
living neurospheres after different treatments was mea-
sured using an inverse confocal microscope (LSM 510
META; Carl Zeiss, Oberkochen, Germany) and ImageJ
software (National Institute of Health, USA) as previous
report [25].
BrdU Labeling for the Cells of Proliferation Assay
For bromodeoxyuridine (BrdU) labeling, 72 h after the
above treatments, 10 lM BrdU was applied to the cultures
for 2 h to label the nuclei of proliferating cells. Then,
immunocytochemistry on the cultures was performed to
detect BrdU positive cells after fixation with 4% PFA.
Briefly, the cultures were denatured in 2 N HCl at 37C for
30 min and rinsed in 0.1 M borax acid buffer (pH 8.5) at
room temperature for 10 min. Then, they were blocked
with 1% bovine serum albumin, 10% normal goat serum,
and 0.3% Triton X-100 in 0.01 M PBS for 1 h at room
temperature. After that, cultures were incubated with
mouse anti-BrdU antibody (1:1,000, Sigma, MO, USA)
overnight at 4C and incubated with fluorescent Alexa
Fluor 488 or 568 goat anti-mouse secondary antibody
(1:400, Molecular Probes, CA, USA) for 2 h at room
temperature. Finally, the nuclei of all the cells were
counterstained with DAPI (Sigma, MO, USA). A total
thirty-six cultures (six cultures in each group) was used for
the proliferation assay.
After immunostaining, the number of immunopositive
cells in each culture was counted using a 920 objective.
Five visual fields were selected on the edge of up, down,
right and left, and the central of each slide, which is a
total of 30 visual fields were counted for each parameter.
DAPI-stained cells, representing the total cell number, and
BrdU-immunoreactive cells in each field were counted.
Percentages for each antibody-immunoreactive cells were
calculated.
Western Blotting for Notch1 and Hes 5
Cells treated with sNgR-Fc, MAG or MW167 were plated
at 1.0 9 106 cells/ml in flasks and were collected 72 h
later for Notch1 analyses using Western blotting. The cells
were trypsinized, washed in cold 0.01 M PBS and collected
Neurochem Res (2011) 36:2363–2372 2365
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as pellets by centrifugation at 1,500 rpm for 5 min. The
cell pellet was then resuspended in 80 ll of radioimmu-
noprecipitation (RIPA) buffer [1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 10 lg/ml PMSF (phen-
ylmethylsulfonyl fluoride)], 20 lg/ml Aprotinin, 10 lg/ml
Leupeptin, 100 mM sodium orthovanadate, in PBS and
incubated on ice for 30 min. The protein lysate was then
centrifuged at 13,500 rpm for 20 min at 4C. The super-
natant was collected and measured for the protein con-
centration using the Dc Protein Assay Kit (Bio-Rad,
Hercules, CA, USA). A 20 lg aliquot of protein from each
sample was subjected to 8–12.5% SDS–polyacrylamide gel
electrophoresis and transferred onto PVDF membrane. The
membranes were blocked with 5% nonfat dry milk and 2%
bovine serum albumin in Tris-buffered saline containing
0.1% Tween 20 (TBST) for 1 h at room temperature.
Incubation with rabbit anti-Notch1 (1:1,000, Millipore,
Temecula, CA, USA) antibody against NICD or rabbit anti-
Hes 5 (1:1,000, Abcam, CB, UK) was performed for 16 h
at 4C. After washing, the membranes were incubated with
horseradish peroxidas-conjugated goat anti-rabbit antibody
(1:2,000, Dako, Denmark) in 5% non fat dry milk and 2%
bovine serum albumin in TBST for 1 h at room tempera-
ture and immunoreactive proteins were detected using the
enhanced chemiluminescence method (ECL, Amersham,
Piscataway, NJ, USA). Protein loading was controlled
using a goat against anti-actin antibody (1:2,000, C-11,
Santa Cruz Biotechnology, CA, USA). The experiments for
Western blotting were repeated 3 times, and representative
data is shown.
TUNEL Staining for Apoptosis
Neurospheres were prepared, cultured and collected as
described above, with either 500 ng/ml sNgR-Fc or neur-
osphere medium alone. After fixation, an In Situ Cell Death
Detection Kit FITC (Roche, Mannheim, Germany) was
used for immunocytochemical detection of apoptosis,
based on labeling of DNA strand breaks (TUNEL tech-
nology) according to the manufacturer’s instructions.
Fluorescein isothiocyanate (FITC) fluorescence was mon-
itored using an inverse confocal laser scanning microscope.
As positive control, neurospheres were treated with DNAse
(2,000 U/ml, Sigma, Deisenhofen, Germany). As negative
control, labeling solution containing FITC was used.
Data and Statistical Analysis
The values presented are mean ± SEM. Statistical analysis
was performed using one-way analysis of variance
(ANOVA) followed by post-hoc tests (Student-Neuman-
Keuls) for comparisons of results obtained from more than
two groups. Data were analyzed statistically with the
software SPSS 12.0. P \ 0.05 was considered statistically
significant.
Results
Characterization of Neural Progenitor Cells Derived
from the Hippocampus
In the presence of epidermal growth factor and basic
fibroblast growth factor, the hippocampus-derived neural
progenitor cells proliferated quickly to form small clusters
and then to larger neurospheres floating within the culture
medium in 3–7 days. Immunocytochemistry revealed that
the cells in neurospheres were positive for Nestin
(Fig. 1a–c). The differentiation potential of NPCs was
evaluated 3 days after mitogens were removed and were
cultured in the presence of 10% fetal bovine serum (FBS).
Neuronal cells that had differentiated from the neuro-
spheres were confirmed by their immunoreactivity for
bIII-Tubulin (Fig. 1d–f). The differentiated cells were also
immunoreactive for glial fibrillary acidic protein (GFAP)
(for astrocytes) (Fig. 1g–i) and Rip (for oligodentrocytes)
(Fig. 1j–l). It showed that these neurospheres could dif-
ferentiate into neurons, oligodentrocytes and astrocytes
simultaneously.
NogoA was Expressed in NPCs in Vitro
Cultured NPCs stained strongly for NogoA (Fig. 2). We
also confirmed that NogoA was coexpressed with Nestin
(Fig. 2a–d). The proportion of NogoA?/Nestin? was
98.2 ± 1.23%.
sNgR-Fc Activated the Proliferation of NPCs
We next investigated the effect of sNgR-Fc on the prolif-
eration of NPCs in culture. NPCs were treated for up to
3 days with sNgR-Fc in different concentrations (0, 50,
500/ml and 1,000 ng/ml). There was significant difference
for the treatment of sNgR-Fc on day 1 [F(3, 20) = 2.341;
P \ 0.01], day 2 [F(3, 20) = 4.437; P \ 0.01] and day 3
[F(3, 20) = 6.674; P \ 0.001]. There was significant
increase in the total number of cells in the 500 ng/ml and
1,000 ng/ml groups compared to the control group on day
1, 2 and 3 respectively (Fig. 3a, P \ 0.01). A significant
increase in volume of the neurospheres was also found
after the treatment of sNgR-Fc [F(3, 20) = 8.342;
P \ 0.001] (Fig. 3b). Representative photomicrographs of
neurospheres at 3 days are shown in Fig. 3c (for control)
and Fig. 3d (for 500 ng/ml sNgR-Fc). In order to evaluate
the effects of sNgR-Fc on the induction of apoptosis, the
cells were treated with sNgR-Fc for 3 days and analyzed
2366 Neurochem Res (2011) 36:2363–2372
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Fig. 1 Identification of the cultured neural progenitor cells. a–c The
neurosphere expressed nestin positively. d–f Neurospheres could
differentiate into bIII-Tubulin? cells. g–i Neurospheres could differ-
entiate into Rip? cells. j–l Neurospheres could differentiate into
GFAP (glial fibrillary acidic protein) positive cells. Cultured neural
progenitor cells were counterstained with 40,6-diamidino-2-phenylin-
dole (DAPI)
Fig. 2 The expression of NogoA in the cultured neuronal progenitor
cells. NogoA expressed in neural progenitor cells (arrows). NogoA
staining (green) (a), Nestin staining (red) (b) demonstrates the
co-localization of NogoA and Nestin in neural progenitor cells
(d) (arrows). The nucleus was counterstained with DAPI (40,6-
diamidino-2-phenylindole) (c)
Neurochem Res (2011) 36:2363–2372 2367
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for apoptosis using a TUNEL assay (Fig. 3e). DNAse
treatment as a positive control resulted in nearly 75%
TUNEL-positive nuclei. Label solution as a negative con-
trol gave no positive signal. Few apoptotic nuclei were
detected and there was no difference between the control
and sNgR-Fc-treated groups. These results suggest that the
effect of sNgR-Fc on the increase of NPCs number might
be a result of proliferation, and not because of the reduction
of cells through apoptosis.
Next, we examined whether the increased new cells
were derived from NPCs. We analyzed progenitor cell
proliferation with BrdU incorporation. This technique has
been extensively used to measure DNA replication during
proliferation of mammalian cells. We found that there was
significant different in the cell proliferation with BrdU
incorporation [F(5, 24) = 12.465; P \ 0.001]. The amount
of BrdU incorporation rose and was higher in 500 ng/ml
and 1,000 ng/ml groups compared to the control (Fig. 4a–
d, g, P \ 0.01). Here we also examined the effect of sNgR-
Fc on the proliferation of NPCs via counting DAPI positive
cells. The total number of DAPI showed that there was
more cells after sNgR-Fc treatment (500 ng/ml or 1 lg/ml)
[F(5, 24) = 11.128; P \ 0.001] (Fig. 4h).
MAG Inhibits the Proliferative Effect of sNgR-Fc
on NPCs
In order to investigate the mechanism by which sNgR-Fc
promotes the proliferation of NPCs, we added MAG into
the culture medium. The NgR-Fc fusion protein can
directly bind with MAG-Fc [15]. Using the BrdU incor-
poration technique, we found that the ability of sNgR-Fc
(500 ng/ml) to promote the ratio of BrdU incorporation
was clearly inhibited after the administration of MAG-Fc
(Fig. 4e, g). It suggests that sNgR-Fc may promote the
proliferation of NPCs by inhibiting the action of myelin
proteins such as MAG.
sNgR-Fc Activated Notch1 in NPCs
We investigated the level of Hes5 and NICD in sNgR-Fc
treated NPCs using Western blotting (Fig. 5a). Significant
differences among Hes 5 [F(5, 12) = 5.624; P \ 0.001]
and NICD [F(5, 12) = 8.366; P \ 0.001] levels were
subsequently revealed by ANOVA analysis. The levels of
Hes5 were higher for sNgR-Fc (500 ng/ml) compared to
control treatment. The levels of NICD were higher for
sNgR-Fc (50 ng/ml) compared to control treatment, peaked
for 500 ng/ml sNgR-Fc treatment and then declined
slightly in the 1,000 ng/ml sNgR-Fc group. MW167, an
inhibitor of the Notch1 signaling pathway, significantly
blocked the activation of Notch1 by sNgR-Fc (Fig. 5a, b).
Using the BrdU incorporation technique, we found that
MW167 significantly inhibited the ability of sNgR-Fc
(500 ng/ml) to promote the ratio of BrdU incorporation
(Fig. 4f, g). Furthermore, we found that the administration
of MAG-Fc blocked the activation of Notch1 with the
treatment of sNgR-Fc (Fig. 5a, b). These data further
suggest that sNgR-Fc may promote the proliferation of
NPCs by inhibiting the activity of myelin proteins. We next
demonstrated that Notch1 was coexpressed with Nestin in
the NPCs using immunocytochemistry. Figure 5e, f shows
Fig. 3 Enhanced proliferation of neural progenitor cells with the
treatment of sNgR-Fc in vitro. Neural progenitor cells (NPCs) were
treated for up to 3 days with different concentration of sNgR-Fc (0,
50, 500 and 1,000 ng/ml). The total cell number was quantified.
a There was an increase in the number of the cells with the treatment
of sNgR-Fc. P \ 0.01 compared to control group in the same time
point. b Quantification of neurosphere volume. sNgR-Fc-treated
neurospheres show significantly increased volume compared to
untreated neurospheres (*P \ 0.01), six cultures for each group.
c–d Photographs of neurospheres, 3 days after plating, show larger
neurospheres after sNgR-Fc treatment (500 ng/ml) (d) than in control
neurospheres (c). e NgR-Fc rarely triggers apoptosis in NPCs.
Apoptosis was detected using TUNEL with FITC-conjugated dUTP
for the neurospheres. Positive control cultures were treated with
DNAse I to generate nicked DNA (e1). Terminal deoxynucleotidyl
transferase was omitted for negative controls (e2). Few apoptotic
nuclei were detected and there was no difference between the control
(e3) and sNgR-Fc-treated (e4) groups
2368 Neurochem Res (2011) 36:2363–2372
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Fig. 4 sNgR-Fc increased bromodeoxyuridin incorporation. Merged
images of bromodeoxyuridin (BrdU) and 40,6-diamidino-2-phenylindole
(DAPI). The NPCs were treated as described below for 3 days and then
pulsed with BrdU (10 lM) for 2 h. a The control group, cultured neural
progenitor cells (NPCs) receivedno further treatment. b–d Cultured NPCs
received treatment of different dosage of sNgR-Fc. e Cultured NPCs
received treatment with sNgR-Fc (500 ng/ml) plus myelin-associated
glycoprotein (MAG). f Cultured NPCs received treatment with sNgR-Fc
(500 ng/ml) plus MW167, a Notch1 inhibitor. sNgR-Fc increased the
ratio of BrdU-positive neural progenitor cells in dosage-dependent
manners, while MAG or MW167 decreased such increased ratio of BrdU
incorporation. g A percentage of BrdU-positive cells in total number of
cells with different treatments. h The total number of DAPI positive cells
five visual fields in different groups. In g, h, *P \0.05, #P \0.01
compared with control group. Open triangle P \ 0.01 compared to
500 ng/ml group. Six cultures for each group (Mean ± SEM)
Neurochem Res (2011) 36:2363–2372 2369
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representative photomicrographs of Notch1 immunolabel-
ling in NPCs after the treatment of sNgR-Fc (500 ng/ml).
Discussion
The present study aimed to elucidate whether NgR1 fusion
protein promotes the proliferation of NPCs and to examine
the possible signaling mechanisms involved. Our results
demonstrated that: (1) NogoA was expressed in cultured
NPCs; (2) sNgR-Fc promoted NPC proliferation; (3) MAG
reversed the proliferative effect of sNgR-Fc on NPCs. (4)
sNgR-Fc activated Notch1 and a Notch1 inhibitor reversed
the effect of sNgR-Fc on NPC proliferation.
Effect of NgR1 Fusion Protein on NPC Proliferation
NgR1 is associated with axon regeneration and neurite
growth. NgR1 is expressed in neurons in different CNS
regions, such as the cortex, subventricular zone and dentate
subgranular zone; and upregulated after brain ischemic
injury [26]. In this study we identified that the NPCs in the
neurosphere and the single NPC strongly expressed NgR1.
The NgR1 ecto-domain, sNgR1 is an NgR1 antagonist and
promotes axon regeneration after spinal cord injury [12,
15], stroke [14] or dorsal root rhizotomy [12, 16]. Our data
suggest, in addition to axon regeneration, sNgR-Fc also
promotes the proliferation of NPCs.
Neural stem cells are characterized by the ability to
undergo cell division and to differentiate into multiple
cell types, e.g. neurons or glial cells. When stimulated by
growth factors or cytokine, the NPCs could generate
cleavage of asymmetry. Recently, much attention are
focused on the therapeutic potential of neural stem cells
to treat neurological disorders such as spinal cord injury
[27, 28], stroke and Parkinson’s disease [29, 30]. The
factor(s) responsible for the proliferation and differentia-
tion of NPCs has been the subject of intense investigation
because identification of regulators of NPCs may allow
for their eventual manipulation in the CNS as therapies to
replace the injured CNS neurons. We have confirmed
including the use of BrdU incorporation experiments, a
significant increase in the number of the cells after sNgR-
Fc treatment. In addition, few apoptotic nuclei were
detected in cells after sNgR-Fc-treatment. This suggests
that the effect of sNgR-Fc on the increase in the number
of NPCs may be linked to proliferative than anti-apoptotic
mechanisms.
Fig. 5 Notch 1 expression in neural progenitor cells. a The treated
neural progenitor cells (NPCs) with sNgR-Fc (500 ng/ml), MAG
(myelin-associated glycoprotein) or MW167 (a Notch1 inhibitor)
were used for Notch1 activation using Western blotting. b Quantita-
tive analysis of Western blotting. The levels of NICD (Notch
intracellular domain) and Hes 5 were increased with the different
dosages of sNgR-Fc, but were reversed by the administration of MAG
and MW167. *P \ 0.05, **P \ 0.01 compared to the control group,
MW167 and MAG-Fc groups. #P \ 0.05, ##P \ 0.01 compared to the
control group. The experiments were repeated 3 time. c–f Coexpres-
sion of Notch 1 (green) with Nestin (red) in the cultured NPCs after
sNgR-Fc treatment (500 ng/ml). The nucleus was counterstained with
DAPI (40,6-diamidino-2-phenylindole)
2370 Neurochem Res (2011) 36:2363–2372
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Molecular Mechanism of sNgR-Fc on NPC
Proliferation
We also examined the possible mechanism of the effect of
sNgR-Fc on the proliferation of NPCs. Nogo is expressed in
three distinct isoforms, NogoA, NogoB and NogoC, which is
known as one of the myelin inhibitors that induces growth
conecollapse and inhibit neurite outgrowth. Cell prolifera-
tion was inhibited significantly in the NogoC overexpressed
PC12 cell which was used as a neuronal model [31]. If NPCs
derived from the spinal cords of rats were allowed to dif-
ferentiate in the presence of Nogo-P4, the average neurite
length and the percentage of differentiated neurons were
decreased [7]. NogoA was also reported to be expressed in
the oligodendrocyte progenitor cells [9]. Much NogoA was
observed in all of the development periods in rat hippo-
campus, and especially in the embryonic and neonatal rats
[32]. In this study, we identified that there was NogoA
expression in the NPCs. The NogoA expressed in NPCs has
the potential to inhibit the proliferation of NPCs. The NgR1
has been shown to constitute a site of signal convergence for
three axon inhibitory proteins found in CNS myelin [33].
Blockade of NgR-dependent signaling by sNgR1 allows an
assessment on the significance of summated inhibition from
NogoA, MAG, and OMgp rather than inhibiting individual
NgR ligands as there are several reported in the literature
aside from myelin molecules such as LINGO-1, p75 and
Troy. Since the expression of these molecules in NPCs are
unclear or found at a later stage e.g. LINGO-1 [9], it is
possible that sNgR-Fc may promote the proliferation of
NPCs by reversing the inhibitive effect of NogoA in partic-
ular that of the Nogo-66 loop. This is because MAG that also
binds NgR1; eliminated the proliferative effect of sNgR-Fc.
It will be interesting to verify if the amino-terminus of
NogoA would also participate in this process. Reagents such
as IN-1 antibody will be useful tools for delineating the
NogoA epitopes involved in NPC proliferation.
The Signaling Pathway for sNgR-Fc Stimulated NPC
Proliferation
Notch1 plays a pivotal role in the regulation of vertebrate
neurogenesis [34]. During this process, Notch-mediated
cell–cell interaction is essential for maintaining dividing
cells and subsequent generation of cell type diversity. Upon
activation by Notch ligands, NICD is cleave, released from
the whole receptor, and activated transcription of its
downstream target genes Hes 1 and Hes 5 [19]. Activation
of Notch inhibits cellular differentiation, and abnormality
of the Notch pathway leads to premature neuronal differ-
entiation, the lack of some cell types, and severe defects of
tissue morphogenesis [35]. Here we showed that the
administration of sNgR-Fc activated Notch1, suggesting
that sNgR-Fc may stimulate the proliferation of NPCs by
activation of Notch1 or its downstream molecules. These
effects could be abolished by Notch1 inhibitor suggesting
specificity. It will be of interest to test if the gamma-
secretase activity is directly related to NPC proliferation.
Our data suggest that sNgR-Fc stimulated NPC prolifera-
tion via activation of the Notch pathway.
Our data indicate that sNgR-Fc promotes the prolifera-
tion of NPCs in vitro via the Notch1 signaling pathway.
sNgR-Fc may provide an attractive therapeutic strategy of
neuronal repair for treating CNS injuries and neurodegen-
erative disorders.
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